Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734922 | 0.96 | SMN1; SMN2 (0.39) | SMN1; SMN2HPGDHTTLMNATSHR | |
| SCHEMBL181009 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTLMNA | |
| SCHEMBL1255461 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTLMNA | |
| SCHEMBL180975 | 0.92 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTTSHRHSD17B10 | |
| SCHEMBL8191582 | 0.91 | HPGD (0.36) | SMN1; SMN2HPGDHTT | |
| SCHEMBL16580092 | 0.91 | HPGD (0.34) | SMN1; SMN2HPGDHTTLMNATSHR | |
| SCHEMBL20528878 | 0.89 | HPGD (0.32) | SMN1; SMN2HPGDHTTLMNA | |
| SCHEMBL23768443 | 0.86 | HPGD (0.33) | SMN1; SMN2HPGDHTT | |
| SCHEMBL21117960 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2HPGDHTTLMNATSHR | |
| SCHEMBL8735537 | 0.85 | HPGD (0.37) | SMN1; SMN2HPGDHTTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015038426-A1 | SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
| US-5843634-A | Genetically engineered enzymes and their conjugates for diagnostic assays | ABBOTT LABORATORIES (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0688364-A4 | GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS | ABBOTT LAB (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0688364-A1 | GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS | ABBOTT LABORATORIES (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994020636-A9 | GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS | — | 1994-11-24 | — | — | WO | disclosed |
| WO-1994020636-A1 | GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS | ABBOTT LABORATORIES (US) | 1994-09-15 | — | — | WO | disclosed |